Clinical Trial Update: Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating neoadjuvant adebrelimab for resectable esophageal squamous cell carcinoma, comparing 2 versus 4 cycles; currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Adebrelimab (adebrelimab)

Snippet

Sponsor: Tang-Du Hospital | Conditions: Esophageal Cancer | Phase 2 | Status: RECRUITING